UBE2C and neoplasm: Consistent with our in vitro findings, A549-bearing mice treated with IT3 siRNAs exhibited a rapid tumor growth curve and shortened survival time compared to the scramble group (Figure 4c and d), indicating that the SLIT3/UBE2C/Wnt axis promotes NSCLC progression and chemoresistance.